Objective: To establish the rate of clinical recurrence of critical limb ischemia (CLI) in diabetic patients with ischemic foot ulcers (DFUs) treated by percutaneous transluminal angioplasty (PTA). Approach: The study group was composed of 304 patients with ischemic DFUs treated by PTA. We evaluated the rate of clinical recurrence of CLI requiring a second PTA (repeated PTA [rePTA]), the factors related to CLI relapse, and the outcomes of rePTA patients. The follow-up was 12.5 ± 6.6 months. Results: Seventy-four of 304 patients (24.3%) needed rePTA. The mean time to rePTA was 3.5 ± 0.64 months. rePTA group in comparison with no rePTA group had lower rate of healing (28.5% vs. 71.9% p = 0.0001), higher rate of ulcer recurrence (20% vs. 10.3% p = 0.03), major amputation (24.3% vs. 4.3% p = 0.0005), and death (33.3% vs. 7.9% p = 0.002). Glycated hemoglobin, type A1C (HbA1c; 2.2 [1.9-2.7] p = 0.02) and dialysis (1.5 [1.4-3.6] p = 0.006) were independently associated to clinical recurrence of CLI after PTA. Innovation: To identify the outcomes of patients with clinical recurrence of CLI and the clinical factors involved to reduce the rate of restenosis after endovascular treatment and improve the rate of limb salvage. Conclusions: Clinical recurrence of CLI is associated with a high rate of nonhealing ulcer recurrence, major amputation, and death. Dialysis and impaired glycemic control were independent predictors of CLI relapse after endovascular treatment.
Objective: To establish the rate of clinical recurrence of critical limb ischemia (CLI) in diabeticpatients with ischemic foot ulcers (DFUs) treated by percutaneous transluminal angioplasty (PTA). Approach: The study group was composed of 304 patients with ischemic DFUs treated by PTA. We evaluated the rate of clinical recurrence of CLI requiring a second PTA (repeated PTA [rePTA]), the factors related to CLI relapse, and the outcomes of rePTApatients. The follow-up was 12.5 ± 6.6 months. Results: Seventy-four of 304 patients (24.3%) needed rePTA. The mean time to rePTA was 3.5 ± 0.64 months. rePTA group in comparison with no rePTA group had lower rate of healing (28.5% vs. 71.9% p = 0.0001), higher rate of ulcer recurrence (20% vs. 10.3% p = 0.03), major amputation (24.3% vs. 4.3% p = 0.0005), and death (33.3% vs. 7.9% p = 0.002). Glycated hemoglobin, type A1C (HbA1c; 2.2 [1.9-2.7] p = 0.02) and dialysis (1.5 [1.4-3.6] p = 0.006) were independently associated to clinical recurrence of CLI after PTA. Innovation: To identify the outcomes of patients with clinical recurrence of CLI and the clinical factors involved to reduce the rate of restenosis after endovascular treatment and improve the rate of limb salvage. Conclusions: Clinical recurrence of CLI is associated with a high rate of nonhealing ulcer recurrence, major amputation, and death. Dialysis and impaired glycemic control were independent predictors of CLI relapse after endovascular treatment.
Authors: S Jacqueminet; A Hartemann-Heurtier; R Izzillo; P Cluzel; J L Golmard; G Ha Van; F Koskas; A Grimaldi Journal: Diabetes Metab Date: 2005-09 Impact factor: 6.041
Authors: Joseph Lindsay; Arvind K Sharma; Daniel Canos; Mohan Nandalur; Ellen Pinnow; Sue Apple; Giacomo Ruotolo; Mevan Wijetunga; Ron Waksman Journal: Cardiovasc Revasc Med Date: 2007 Jan-Mar
Authors: Randall R De Martino; Jens Eldrup-Jorgensen; Brian W Nolan; David H Stone; Julie Adams; Daniel J Bertges; Jack L Cronenwett; Philip P Goodney Journal: J Vasc Surg Date: 2014-01-16 Impact factor: 4.268
Authors: Gilles Lemesle; Laurent Bonello; Axel de Labriolle; Gabriel Maluenda; Asmir I Syed; Sara D Collins; Itsik Ben-Dor; Rebecca Torguson; Kimberly Kaneshige; Zhenyi Xue; William O Suddath; Lowell F Satler; Kenneth M Kent; Joseph Lindsay; Augusto D Pichard; Ron Waksman Journal: Am J Cardiol Date: 2009-07-01 Impact factor: 2.778
Authors: Marcello Romiti; Maximiano Albers; Francisco Cardoso Brochado-Neto; Anai Espinelli S Durazzo; Carlos Alberto Bragança Pereira; Nelson De Luccia Journal: J Vasc Surg Date: 2008-04-18 Impact factor: 4.268
Authors: Xiaoyan Jiang; Yi Yuan; Yu Ma; Miao Zhong; Chenzhen Du; Johnson Boey; David G Armstrong; Wuquan Deng; Xiaodong Duan Journal: J Diabetes Res Date: 2021-05-08 Impact factor: 4.061